



Alzheimer's & Parkinson's Disease: Open Access

Editorial

Therapeutic Perspectives of Alzheimer's Disease - ②

Zhao Zhong Chong*

Department of Anesthesiology, University of Illinois at Chicago, Chicago, Illinois

***Address for Correspondence:** Zhao Zhong Chong, Department of Anesthesiology, University of Illinois at Chicago, 835 S. Wolcott Street, Bldg 935 E713, Chicago, IL, 60612. Email : zzchong@uic.edu

Submitted: 10 December 2015; **Approved:** 28 December 2015; **Published:** 31 December 2015

Citation this article: Chong ZZ. Therapeutic Perspectives of Alzheimer's Disease . Alzheimers Parkinsons Dis Open Access. 2015;1(1): 010-012.

Copyright: © 2015 Chong ZZ. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Alzheimer's disease (AD) is the most common dementia that leads to a progressive deterioration of cognitive function with memory loss. With increasing ageing population in our society, AD influences more and more people in their late life. Although significant advances have been made in the pathological process of AD after its discovery for over a century, the effects targeting the assumed clarified pathogenesis for the treatment of AD are still elusive.

The two pathologic hallmarks of AD have been considered as extracellular plaques of amyloid- β peptide aggregates and intracellular neurofibrillary tangles composed of hyperphosphorylated microtubular protein tau [1]. The β -amyloid deposition constitutes the plaques that are composed of a 39–42 amino acid peptide ($A\beta$), which is the proteolytic product of the amyloid precursor protein (APP) [2]. The hyperphosphorylated tau protein aggregates to form insoluble particles in cells and cause intracellular neurofibrillary tangles. Since the discovery of the pathological features of AD, tremendous efforts have been made to fight against the progress of AD. The immunotherapy can represent an innovative strategy developed in recent years.

The amyloid cascade hypothesis has been formulated over last 20 years [3]. The key of this theory is that accumulation and aggregation of $A\beta$ initiate the neurodegenerative cascade that leads to neuronal loss and cognitive decline. In this respect, the immunotherapy aiming to prevent $A\beta$ deposition and clean the existing $A\beta$ has been developed. The primary results are encouraging with passive immunotherapy, which demonstrated that application of monoclonal antibody against some epitopes of $A\beta$ reduced the $A\beta$ burden and prevented $A\beta$ aggregation [4,5]. However, the clinical efficacy was not satisfactory, no cognitive benefit has been achieved in AD patients with passive immunotherapy against $A\beta$ [6]. In a recent study in animal model of AD, $A\beta$ -targeting antibody fails to repair neuronal dysfunction by using *in vivo* two-photon images in mice, besides, it can increase the neuronal hypersensitivity in the cerebral cortex [7], which may be a feature of early neuronal dysfunction in AD [8].

Although active immunity against $A\beta$ is more effective to remove or clarify the amyloid plaques, immunization with $A\beta$ did not prevent the progression of AD and did not even improve the survival of patients [9], not to mention of increased risk of meningoencephalitis due to requirement of adjuvant for the vaccine [10]. In this respect, DNA vaccine may hold some promise, since no adjuvant is required for DNA vaccine.

The above results give another reason to argue against the amyloid cascade hypothesis [11]. In fact, the $A\beta$ plaque and tau pathology have been proposed to function independently [12]. The amyloid load has been considered to have a poor correlation with cognitive deficit, in contrast, tau pathology and neurofibrillary tangle are more closely correlated with the severity of the disease [13,14]. The immunotherapy targeting tau protein has therefore become a new promising opportunity. In animal models, anti-tau antibodies have been demonstrated to reduce the tau aggregates and improve the

motor neuronal function in mice [15,16]. The clinical efficacy for tau immunotherapy is expected in the near future.

With the development of second generation of DNA sequencing techniques, lower and more reliable genetic screening service for dementia is becoming more and more accessible for cases with genetic mutation. With that in hand, early application of immunotherapy becomes possible and may achieve considerable cognitive benefits.

The complicated nature of pathogenesis of AD indicates that comprehensive measurement is required to prevent or block the development of this disorder. Other therapeutic strategies aiming to prevent the pathological cascade are also emerging, such as anti-oxidative stress, anti-inflammation, and cell therapy, every minimal efficacy of which would be counted to contribute to the future therapeutic renovation for AD. For example, long-term treatment with an antagonist of corticotropin-releasing factor, a stress-coping hormone that has been associated with pathology of tau protein and amyloid, reduces the brain's stress circuitry activity and slows the progressive cognitive decline in mice [17]. Neural stem cell therapy has also been demonstrated to reduce the amyloid plaques, prevent neuronal loss, and improve the synaptic plasticity and cognitive function in mouse model of AD [18,19].

With a new journal, SRL Alzheimer's & Parkinson's disease, has been launched, the researchers fighting against AD and Parkinson's disease will own a new platform to communicate and this may provide more robust motivation to push the development of novel therapies for these degenerative diseases forward. Since more and more people are jumping into the research field of AD and Parkinson's disease, it is also the opportunity for this journal to establish its own reputation through recruiting high quality papers and attracting prestigious scientists to input their cutting-edge approaches and discoveries in this journal.

REFERENCES

1. Tiraboschi P, Sabbagh MN, Hansen LA, Salmon DP, Merdes A, et al. Alzheimer disease without neocortical neurofibrillary tangles: "A second look". *Neurology* 2004; 62(7):1141-1147.
2. Chong ZZ, Li F, Maiese K: Stress in the brain: Novel cellular mechanisms of injury linked to alzheimer's disease. *Brain Res Brain Res Rev* 2005; 49(1):1-21.
3. Hardy JA, Higgins GA: Alzheimer's disease: The amyloid cascade hypothesis. *Science* 1992; 256(5054):184-185.
4. Solomon B, Koppel R, Hanan E, Katzav T: Monoclonal antibodies inhibit *in vitro* fibrillar aggregation of the alzheimer beta-amyloid peptide. *Proc Natl Acad Sci U S A* 1996; 93(1):452-455.
5. Solomon B, Koppel R, Frankel D, Hanan-Aharon E: Disaggregation of alzheimer beta-amyloid by site-directed mab. *Proc Natl Acad Sci U S A*. 1997; 94(8):4109-4112.
6. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, et al. Phase 3 trials of solanezumab for mild-to-moderate alzheimer's disease. *N Engl J Med* 2014; 370(4):311-321.
7. Busche MA, Grienberger C, Keskin AD, Song B, Neumann U, et al. Decreased amyloid-beta and increased neuronal hyperactivity by immunotherapy in alzheimer's models. *Nat Neurosci* 2015.

Cite this Article: Chong ZZ. *Therapeutic Perspectives of Alzheimer's Disease*. *Alzheimers Parkinsons Dis Open Access*. 2015;1(1): 010-012.

8. Busche MA, Konnerth A: Neuronal hyperactivity--a key defect in alzheimer's disease? *Bioessays* 2015: 37(6):624-632.
9. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, et al. Long-term effects of abeta42 immunisation in alzheimer's disease: Follow-up of a randomised, placebo-controlled phase i trial. *Lancet* 2008: 372(9634):216-223.
10. Tse DM, Sham MM, Ng DK, Ma HM: An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: An open uncontrolled prospective study in a chinese population. *Palliat Med* 2003: 17(2):206-211.
11. Herrup K. The case for rejecting the amyloid cascade hypothesis. *Nat Neurosci* 2015: 18(6):794-799.
12. Small SA, Duff K. Linking abeta and tau in late-onset alzheimer's disease: A dual pathway hypothesis. *Neuron* 2008; 60(4):534-542.
13. Pedersen JT, Sigurdsson EM. Tau immunotherapy for alzheimer's disease. *Trends Mol Med* 2015: 21(6):394-402.
14. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in alzheimer's disease. *Neurology* 2003; 60(9):1495-1500.
15. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. *J Neurochem* 2011: 118(4):658-667.
16. Chai X, Wu S, Murray TK, Kinley R, Cella CV, et al. Passive immunization with anti-tau antibodies in two transgenic models: Reduction of tau pathology and delay of disease progression. *J Biol Chem* 2011: 286(39):34457-34467.
17. Zhang C, Kuo CC, Moghadam SH, Monte L, Campbell SN, et al. Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of alzheimer's disease. *Alzheimers Dement* 2015.
18. Blurton-Jones M, Spencer B, Michael S, Castello NA, Agazaryan AA, et al. Neural stem cells genetically-modified to express neprilysin reduce pathology in alzheimer transgenic models. *Stem Cell Res Ther* 2014: 5(2):46.
19. Ager RR, Davis JL, Agazaryan A, Benavente F, Poon WW, et al. Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of alzheimer's disease and neuronal loss. *Hippocampus* 2015: 25(7):813-826.

Cite this Article: Chong ZZ. *Therapeutic Perspectives of Alzheimer's Disease*. *Alzheimers Parkinsons Dis Open Access*. 2015;1(1): 010-012.